Shenyou Nie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shenyou Nie has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Yi He
Chongqing Medical University
16 shared publicationsYijie Xiao
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
10 shared publicationsLijie Lv
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Urology and Department of Cancer Center of the Second Affiliated Hospital, College of Pharmacy
9 shared publicationsJia Zheng
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Urology and Department of Cancer Center of the Second Affiliated Hospital, College of Pharmacy
7 shared publicationsDan Ni
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, College of Pharmacy
6 shared publications- Hai-Xin Yuan
Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention (Ministry of Education), Department of Urology and Department of Cancer Center of the Second Affiliated Hospital, College of Pharmacy
6 shared publications
Latest Publications
- 17 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 17825-17844
Modular Access to Diverse Soluble Epoxide Hydrolase Degraders as Potential Agents for Alleviating LPS-Induced Acute Inflammation
Bifunctional soluble epoxide hydrolase (sEH) represents an attractive therapeutic target for inflammation-associated disorders. Targeted protein degradation (TPD) offers new opportunities for targeting and blocking the enzymatic function of sEH, thereby ameliorating inflammation-related diseases. Herein, a diversity-oriented synthesis of 24 proteolysis-targeting chimeras (PROTACs) and 5 hydrophobic tag-targeted degraders (HyTTDs) was successfully facilitated by a Ugi-4CR reaction. Notably, the E3 ubiquitin ligase RNF126 and hydrophobic tag (HyT) ligands are delicately embedded in the degraders and exhibit moderate to good degradative activities toward sEH. After comprehensive biological screening, the PROTAC molecule 1d was found to have the highest degradation potency (DC50 = 2.9 nM) and exhibited satisfactory degradative pharmacokinetic properties within 6 h, which further proved to significantly attenuate LPS-induced in vivo acute inflammation, highlighting its therapeutic utility.
- 17 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 17825-17844
Modular Access to Diverse Soluble Epoxide Hydrolase Degraders as Potential Agents for Alleviating LPS-Induced Acute Inflammation
Bifunctional soluble epoxide hydrolase (sEH) represents an attractive therapeutic target for inflammation-associated disorders. Targeted protein degradation (TPD) offers new opportunities for targeting and blocking the enzymatic function of sEH, thereby ameliorating inflammation-related diseases. Herein, a diversity-oriented synthesis of 24 proteolysis-targeting chimeras (PROTACs) and 5 hydrophobic tag-targeted degraders (HyTTDs) was successfully facilitated by a Ugi-4CR reaction. Notably, the E3 ubiquitin ligase RNF126 and hydrophobic tag (HyT) ligands are delicately embedded in the degraders and exhibit moderate to good degradative activities toward sEH. After comprehensive biological screening, the PROTAC molecule 1d was found to have the highest degradation potency (DC50 = 2.9 nM) and exhibited satisfactory degradative pharmacokinetic properties within 6 h, which further proved to significantly attenuate LPS-induced in vivo acute inflammation, highlighting its therapeutic utility.
- 16 July 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
Synthesis of β-Carboline Derivatives via Rh(III)-Catalyzed Csp–Csp 3 Bond Cleavage Using Alkynyl Quinol as C2 Surrogates
A straightforward access to diverse, highly functionalized β-carboline derivatives from 2-indolyl nitrone and alkynyl quinol has been established. This protocol features rhodium(III)-catalyzed Csp-Csp3 bond cleavage and a Kinugasa-type reaction involving N-O bond cleavage as key steps, enabling the assembly of β-carbolines in moderate to good yields with good anticancer activity.
- 16 July 2026
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
Synthesis of β-Carboline Derivatives via Rh(III)-Catalyzed Csp–Csp 3 Bond Cleavage Using Alkynyl Quinol as C2 Surrogates
A straightforward access to diverse, highly functionalized β-carboline derivatives from 2-indolyl nitrone and alkynyl quinol has been established. This protocol features rhodium(III)-catalyzed Csp-Csp3 bond cleavage and a Kinugasa-type reaction involving N-O bond cleavage as key steps, enabling the assembly of β-carbolines in moderate to good yields with good anticancer activity.
- 27 May 2026
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 28 (24) , 10150-10156
Access to indole-3-urea/carbamate derivatives via rhodium-catalysed Lossen rearrangement: a uniform and safe protocol
In recent years, indole-3-urea/carbamate derivatives have emerged as privileged scaffolds in drug discovery campaigns.
- 27 May 2026
- Published by Royal Society of Chemistry (RSC) in Green Chemistry
- Vol. 28 (24) , 10150-10156
Access to indole-3-urea/carbamate derivatives via rhodium-catalysed Lossen rearrangement: a uniform and safe protocol
In recent years, indole-3-urea/carbamate derivatives have emerged as privileged scaffolds in drug discovery campaigns.
- 30 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11503-11523
Novel Carboline-Based Ferroptosis Inhibitor Ameliorates Acute Liver Injury by Remodeling Phosphatidylcholine
Ferroptosis is an iron-dependent form of cell death caused by phospholipid peroxidation and represents a therapeutic target for acute organ injury. Regulating cellular lipid composition to control peroxidation-prone phospholipids is crucial for modulating ferroptosis. We synthesized 53 carboline derivatives featuring a benzofuro[2,3-b]pyridine scaffold via a rhodium-catalyzed cascade reaction. Phenotypic screening identified compound 4g as a potent ferroptosis inhibitor, with an EC50 value of 93 nM in H9c2 cells. Mechanistically, 4g neither traps radicals nor chelates iron, nor does it regulate ferroptosis-related gene expression; instead, it mediates CEPT1-dependent phosphatidylcholine remodeling to enrich PC-MUFA and suppress lipid peroxidation. In vivo, 4g effectively protects against hepatic ischemia-reperfusion injury, as well as ConA- and APAP-induced acute liver injury, demonstrating its potential as a promising therapeutic agent for ferroptosis-related tissue damage.
- 30 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 11503-11523
Novel Carboline-Based Ferroptosis Inhibitor Ameliorates Acute Liver Injury by Remodeling Phosphatidylcholine
Ferroptosis is an iron-dependent form of cell death caused by phospholipid peroxidation and represents a therapeutic target for acute organ injury. Regulating cellular lipid composition to control peroxidation-prone phospholipids is crucial for modulating ferroptosis. We synthesized 53 carboline derivatives featuring a benzofuro[2,3-b]pyridine scaffold via a rhodium-catalyzed cascade reaction. Phenotypic screening identified compound 4g as a potent ferroptosis inhibitor, with an EC50 value of 93 nM in H9c2 cells. Mechanistically, 4g neither traps radicals nor chelates iron, nor does it regulate ferroptosis-related gene expression; instead, it mediates CEPT1-dependent phosphatidylcholine remodeling to enrich PC-MUFA and suppress lipid peroxidation. In vivo, 4g effectively protects against hepatic ischemia-reperfusion injury, as well as ConA- and APAP-induced acute liver injury, demonstrating its potential as a promising therapeutic agent for ferroptosis-related tissue damage.
- 5 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 303, 118464
Discovery of α-carboline fused benzofuran-containing anticancer agents as rapid apoptosis inducers through intrinsic pathway
- 5 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 303, 118464
Discovery of α-carboline fused benzofuran-containing anticancer agents as rapid apoptosis inducers through intrinsic pathway
- Open Access
- 6 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (3) , 1510-1529
Vitamin A and its analogues modulate MUFAs metabolism to improve ferroptosis and aging by direct targeting of ACSL3
- 6 November 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (3) , 1510-1529
Open AccessVitamin A and its analogues modulate MUFAs metabolism to improve ferroptosis and aging by direct targeting of ACSL3
- 25 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18703-18726
Identification of Benzofuro[2,3-b]pyridine Pseudonatural Product as a Novel Class of Ferritinophagy Inhibitors that Potently Suppress Ferroptosis
Ferroptosis is a form of regulated cell death mediated by iron-dependent phospholipid peroxidation. Pharmacological inhibition of ferroptosis has been considered a promising therapeutic approach for various diseases. In this study, by integrating pseudonatural concepts with our newly developed rhodium-catalyzed C–H activation/Lossen rearrangement/oxa-Michael addition methodology, we rapidly assembled diverse benzofuro[2,3-b]pyridine PNP derivatives and systematically evaluated their antiferroptotic activity. Among these compounds, 4k exhibited significant activity in suppressing ferroptosis. We further elucidated that 4k acts as a novel and specific inhibitor of ferritinophagy by targeting NCOA4 and disrupting its interaction with ferritin. Subsequent results demonstrated that 4k effectively ameliorated ConA-induced acute liver injury. Collectively, our findings indicate that 4k, featuring benzofuro[2,3-b]pyridine PNP scaffolds, acts as a selective inhibitor and could serve as a potential lead compound for further research. This work suggests that pharmacological targeting of the NCOA4-FTH1 interaction represents a promising intervention strategy for ferroptosis-related diseases.
- 25 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18703-18726
Identification of Benzofuro[2,3-b]pyridine Pseudonatural Product as a Novel Class of Ferritinophagy Inhibitors that Potently Suppress Ferroptosis
Ferroptosis is a form of regulated cell death mediated by iron-dependent phospholipid peroxidation. Pharmacological inhibition of ferroptosis has been considered a promising therapeutic approach for various diseases. In this study, by integrating pseudonatural concepts with our newly developed rhodium-catalyzed C–H activation/Lossen rearrangement/oxa-Michael addition methodology, we rapidly assembled diverse benzofuro[2,3-b]pyridine PNP derivatives and systematically evaluated their antiferroptotic activity. Among these compounds, 4k exhibited significant activity in suppressing ferroptosis. We further elucidated that 4k acts as a novel and specific inhibitor of ferritinophagy by targeting NCOA4 and disrupting its interaction with ferritin. Subsequent results demonstrated that 4k effectively ameliorated ConA-induced acute liver injury. Collectively, our findings indicate that 4k, featuring benzofuro[2,3-b]pyridine PNP scaffolds, acts as a selective inhibitor and could serve as a potential lead compound for further research. This work suggests that pharmacological targeting of the NCOA4-FTH1 interaction represents a promising intervention strategy for ferroptosis-related diseases.
- 15 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17046-17064
GLUTs-Facilitated Targeting BRD4 Degradation in Breast Cancer through Carbohydrate-Conjugated PROTACs
Proteolysis-targeting chimeras (PROTACs) are an emerging class of therapeutic agents for anticancer treatments by degrading intracellular proteins via the ubiquitin-proteasome system. However, clinical applications of PROTACs are limited by the undesired normal cell toxicity resulting from off-tissue on-target degradation. To address this, we developed a tumor-selective delivery strategy by conjugating carbohydrate moieties to the ligand of the VHL E3 ubiquitin ligase, which enables targeted degradation of proteins of interest in GLUTs-overexpressing cancer cells. We designed and synthesized two series of carbohydrate and BRD PROTAC (ARV-771) conjugates. These compounds degraded BRD4 in a concentration- and time-dependent manner, with NG-2 showing the highest degradation efficiency. Moreover, NG-2’s degradation effect was GLUTs- and proteasome-dependent, with selective targeting and effective degradation in high GLUTs-expressing cells. Furthermore, NG-2 inhibited tumor growth without significant toxicity in vivo. These findings demonstrate the potential of carbohydrate-PROTAC as a targeted cancer therapy with minimized off-tissue on-target degradation.
- 15 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17046-17064
GLUTs-Facilitated Targeting BRD4 Degradation in Breast Cancer through Carbohydrate-Conjugated PROTACs
Proteolysis-targeting chimeras (PROTACs) are an emerging class of therapeutic agents for anticancer treatments by degrading intracellular proteins via the ubiquitin-proteasome system. However, clinical applications of PROTACs are limited by the undesired normal cell toxicity resulting from off-tissue on-target degradation. To address this, we developed a tumor-selective delivery strategy by conjugating carbohydrate moieties to the ligand of the VHL E3 ubiquitin ligase, which enables targeted degradation of proteins of interest in GLUTs-overexpressing cancer cells. We designed and synthesized two series of carbohydrate and BRD PROTAC (ARV-771) conjugates. These compounds degraded BRD4 in a concentration- and time-dependent manner, with NG-2 showing the highest degradation efficiency. Moreover, NG-2’s degradation effect was GLUTs- and proteasome-dependent, with selective targeting and effective degradation in high GLUTs-expressing cells. Furthermore, NG-2 inhibited tumor growth without significant toxicity in vivo. These findings demonstrate the potential of carbohydrate-PROTAC as a targeted cancer therapy with minimized off-tissue on-target degradation.
- 9 June 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (24) , 6522-6526
Synthesis of γ-Carboline Derivatives via the Rh(III)-Catalyzed Regioselective C–H Activation/[4+2] Annulation Cascade
Transition-metal-catalyzed annulation represents an attractive approach for constructing diverse bioactive molecules while facing challenges like regioselective control. Herein, an efficient assembly of diverse highly functionalized γ-carboline derivatives from 2H-imidazoles and alkynes has been established. This was achieved through a rhodium(III)-catalyzed C-H activation/[4+2] tandem cyclization cascade, facilitating chemo- and regioselective access to γ-carbolines, which exhibit good anticancer activity, in moderate yields.
- 9 June 2025
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 27 (24) , 6522-6526
Synthesis of γ-Carboline Derivatives via the Rh(III)-Catalyzed Regioselective C–H Activation/[4+2] Annulation Cascade
Transition-metal-catalyzed annulation represents an attractive approach for constructing diverse bioactive molecules while facing challenges like regioselective control. Herein, an efficient assembly of diverse highly functionalized γ-carboline derivatives from 2H-imidazoles and alkynes has been established. This was achieved through a rhodium(III)-catalyzed C-H activation/[4+2] tandem cyclization cascade, facilitating chemo- and regioselective access to γ-carbolines, which exhibit good anticancer activity, in moderate yields.
- 23 May 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (22) , 7359-7371
Gold-Catalyzed Conia-Ene Cyclization/Aza-Michael Addition Cascades: Access to Indolinylazepinone PNPs with Anticancer Activity
A modular and streamlined assembly of diverse indolinylazepinone pseudonatural products (PNPs) has been established through post-Ugi gold-catalyzed Conia-ene cyclization/aza-Michael addition cascades. Mechanistic studies revealed that cationic gold acts as a unique soft Lewis acid to furnish this protocol through double activation. This approach facilitates chemo- and regioselective access to target PNPs in moderate to good yields with remarkable anticancer activity.
- 23 May 2025
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 90 (22) , 7359-7371
Gold-Catalyzed Conia-Ene Cyclization/Aza-Michael Addition Cascades: Access to Indolinylazepinone PNPs with Anticancer Activity
A modular and streamlined assembly of diverse indolinylazepinone pseudonatural products (PNPs) has been established through post-Ugi gold-catalyzed Conia-ene cyclization/aza-Michael addition cascades. Mechanistic studies revealed that cationic gold acts as a unique soft Lewis acid to furnish this protocol through double activation. This approach facilitates chemo- and regioselective access to target PNPs in moderate to good yields with remarkable anticancer activity.